Effects of PEG conjugation on insulin properties

Advanced Drug Delivery Reviews

Volumn 54, Issue 4, 2002, Pages 505-530

  Hinds, Kenneth D ^a   Kim, Sung Wan ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Diabetes; Immunogenicity; Parenteral delivery; PEG protein conjugates; Pharmacokinetics; Poly(ethylene glycol); Protein delivery; Protein stabilization

Indexed keywords

IMMUNOLOGY; INSULIN; PHARMACOKINETICS; POLYMERS; PROTEINS;

CONJUGATION;

POLYETHYLENE GLYCOLS;

GLUCOSE; HUMULINR; INSULIN DERIVATIVE; ISOPHANE INSULIN; MACROGOL INSULIN CONJUGATE; UNCLASSIFIED DRUG;

ALLERGENICITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG ANTIGENICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; GLUCOSE BLOOD LEVEL; IMMUNOGENICITY; INSULIN RELEASE; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

EID: 0037124501     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00025-X     Document Type: Article

References (108)

1. Pancreatic extracts
2. The clinical efficacy of poly(ethylene glycol)-modified proteins
3. Introduction to biotechnical and biomedical applications of poly(ethylene glycol)
4. Proton NMR characterization of poly(ethylene glycols) and derivatives
5. Molecular simulation of protein-PEG interaction
6. Use of functionalized poly(ethylene glycol)s for modification of polypeptides
7. Alteration of the circulating life and antigenic properties of bovine adenosine deamidase in mice by attachment of polyethylene glycol
8. Adenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene-glycol modified adenosine deaminase
9. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase
10. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase
11. Bovine collagen modified by PEG
12. Long-acting growth hormones produced by conjugation with polyethylene glycol
13. Synthesis and biological activity of polyethylene glycol-mouse nerve growth factor conjugate
14. Preparation and properties of polyethylene glycol-trypsin adducts
15. Effects of polyethylene glycol substitution on enzyme activity
16. Modification of E. coli asparaginase with polyethylene glycol: Disappearance and binding activity to anti-asparaginase serum
17. Preparation of a polyethylene glycol: Superoxide dismutase adduct, and examination of its blood circulating life and anti-inflammatory activity
18. Modification of human haemoglobin with polyethylene glycol: A new candidate for blood substitute
19. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol
20. Pharmacokinetics of recombinant granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats
21. Synthesis, isolation, and characterization of conjugates of ovalbumin with monomethoxypolyethylene glycol using cyanuric chloride as the coupling agent
22. Effects of monomethoxypoly (ethyleneglycol) modification of ribonuclease on antibody recognition, substrate accessibility, and conformational stability
23. Synthesis and spectroscopic characterization of insulin derivatives containing one or two poly(ethylene glycol) chains at specific positions
24. Influence of poly(ethylene glycol) insulin on the lipid tissues of experimental animals
25. Improvement of the physicochemical and biopharmaceutical properties of insulin by poly(ethylene glycol) conjugation
26. The uses and properties of PEG-linked proteins
27. Insulin: The structure in the crystal and its reflection in chemistry and biology
28. Studies on the stability of insulin
29. Immunogenicity of recombinant DNA human insulin
30. Resistance and allergy to recombinant human insulin
31. Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA)
32. Immunologic reactions against insulin. II. IgE anti-insulin, insulin allergy and combined IgE and IgG immunologic resistance
33. Insulin allergy: Reaginic antibodies to insulin and pro-insulin
34. Immunologic reactions against insulin. I. IgG anti-insulin and insulin resistance
35. Physical binding of insulin by gamma globulins of insulin resistant patients
36. Affinity of IgG-insulin antibodies to human (recombinant DNA) insulin and porcine insulin in insulin-treated diabetic individuals with and without insulin resistance
37. Complications of insulin therapy
38. Effect of insulin antibodies on insulin pharmacokinetics and glucose utilization in insulin-dependent diabetes mellitus
39. Effect of anti-insulin antibodies on glycemic control in insulin-treated diabetic patients
40. Effect of insulin antibodies and their kinetic characteristics on plasma-free insulin dynamics in patients with diabetes mellitus
41. Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats
42. In vitro and in vivo effects of poly-N-vinylpyrrolidone-insulin
43. Study of insulin action by use of insulin-dextran complex: Uptake of insulin into subcellular fractions and stimulation of pyruvate dehydrogenase in mouse adipocytes
44. 1-phenylalanine
45. Physical stabilization of insulin by glycosylation
46. Synthesis of palmitoyl derivatives of insulin and their biological activities
47. The biological activity and the binding affinity of modified insulins determined on isolated rat fat cells
48. Structure and evolution of insulins: Implications for receptor binding
49. Synthesis and characterization of poly(ethylene glycol)-insulin conjugates
50. Glucose-induced release of glycosylpoly(ethylene glycol) insulin bound to a soluble conjugate of concanavalin A
51. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs
52. Altering the association properties of insulin by amino acid replacement
53. Zinc binding, circular dichroism, and equilibrium sedimentation studies in insulin (bovine) and several of its derivatives
54. Changes in secondary structure follow the dissociation of human insulin hexamers: A circular dichroism study
55. The ultraviolet circular dichroism of bovine insulin and desoctapeptide insulin
56. An analysis of the near ultraviolet circular dichroism of insulin
57. Conformational dynamics of insulin in solution. Circular dichroic studies
58. The relation of conformation and association of insulin to receptor binding; X-ray and circular-dichroism studies on bovine and hystricomorph insulins
59. Quantitative analysis of protein far UV circular dichroism spectra by neural networks
60. The structure of 2Zn pig insulin crystals at 1.5 Å resolution
61. Insulin analogs with improved pharmacokinetic profiles
62. Absorption of injected insulin
63. Monomeric insulins and their experimental and clinical implications
64. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogs in humans
65. The pig as a model for subcutaneous insulin absorption in man
66. Molecular structure of insulin: The insulin monomer and its assembly
67. The self-association of zinc-free bovine insulin
68. Insulin pharmacokinetics
69. Analysis of data from the analytical ultracentrifuge by non-linear least squares techniques
70. Equilibrium ultracentrifugation of dilute solutions
71. A model of insulin fibrils derived from the X-ray crystal structure of monomeric insulin (despentapeptide insulin)
72. Toward understanding insulin fibrillation
73. Suppression of reaginic antibodies with modified allergans. I. Reduction in allerginicity of protein allergans by conjugation to polyethylene glycol
74. Novel site-specific insulin conjugates with enhanced stability and extended action profile for parenteral delivery
75. The immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers - Potential hapten or drug carriers
76. Immunogenicity of glycosylated derivatives of insulin. I. Antibodies to gliadin detected after immunization with insulin and its G-derivatives
77. Alteration of the immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol
78. The molecular weight ratio of monomethoxypolyethylene glycol (mPEG) to protein determines the immunotolerogenicity of mPEG proteins
79. Prevention of collagen-induced arthritis (CIA) by treatment with polyethylene glycol-conjugated type II collagen; Distinct tolerogenic property of the conjugated collagen from the native one
80. Situation of monomethoxypolyethylene glycol covalently attached to lysozyme
81. Depression of T-cell epitope generation by stabilizing hen lysozyme
82. PEG-modified proteins
83. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol)
84. Allergy in experimental mouse tuberculosis
85. Regulation of delayed-type hypersensitivity to pathogens and alloantigens
86. Mechanisms of T cell-mediated immune reactions
87. Role of mast cells in anaphylaxis. Evidence for the importance of mast cells in the cardiopulmonary alterations and death induced by anti-IgE in mice
88. Degranulation of human basophil leukocytes by anti-gamma E antibody
89. Recombinant soluble form of the human high-affinity receptor for IgE prevents anaphylactic shock in mice
90. Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene
91. Suppression of antibody responses by conjugates of antigens and monomethoxypoly(ethylene glycol)
92. Suppression of reaginic antibodies with modified allergans. II. Abrogation of reaginic antibodies with allergans conjugated to polyethylene glycol
93. [Lys(B28), Pro(B29)]-Human insulin: A rapidly absorbed analog of human insulin
94. Evaluation of monomethoxypolyethyleneglycol derivatized superoxide dismutase in blood and evidence for its binding to blood cells
95. Insulin degradation: Progress and potential
96. Structure and properties of pharmacologically active polymers
97. Protein pegylation. New Life for an old technology
98. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): Novel high affinity TNF receptor designed for chronic rheumatoid arthritis
99. Therapeutic antibody fragments with prolonged in vivo half-lives
100. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferonalfa-2b as initial treatment for chronic hepatitis C
101. PEG-Interferon Alfa-2a in patients with chronic hepatitis C
102. PEG-Interferon alfa-2a in patients with chronic hepatitis C and cirrhosis
103. Preparation and characterization of poly(ethylene glycol)ylated human growth hormone antagonist